Loading comparison data...
Medical Disclaimer: This site provides informational comparisons only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before making medication decisions.
Compare Deucravacitinib (Sotyktu) and Risankizumab (Skyrizi) — clinical data, side effects, and patient experiences.
Sotyktu · TYK2 Inhibitor
How it works
Selective allosteric inhibitor of tyrosine kinase 2 (TYK2), blocking IL-23, IL-12, and Type I interferon signalling.
Approved for
Skyrizi · Biologic (IL-23 Inhibitor)
How it works
Humanized monoclonal antibody that selectively binds to the p19 subunit of IL-23, inhibiting IL-23-dependent inflammatory signalling.
Approved for
Estimated frequency (%) based on clinical trial data
No specific warnings
Based on 5 Reddit discussions
Deucravacitinib
40%
positive
5 threads
Risankizumab
0%
positive
0 threads
% of discussions mentioning each side effect
5 Reddit threads analysed for Deucravacitinib
Overall Sentiment
Slightly positive
Comparison Threads
0
Avg Post Score
6 upvotes
Most discussed side effects in community
NEW YORK — Potential upcoming approvals of JAK inhibitors for hidradenitis suppurativa (HS) and vitiligo suggest these drugs are becoming one of the most versatile therapies in dermatology, and their safety for treating skin diseases might be a story of its own. For dermatologic indications, all JAK
Making this post to gather all the experiences with new medicines (and even traditionals if positive) that are currently being used for various type of scarring alopecias, these being: ***Biological medicines*** 1. **Adalimumab** / Humira 2. **Secukinumab** / Cosentyx 3. **IL-23** / Guselkumab ***Im
Anyone in NYS or anyone working in NYS Independent pharmacies know how to order Sotyktu? I tried ordering through Kinray and it's listed as "Special Order". I called Bristol Myers and they stated Cardinal Health Specialty Distribution are authorized to sell the product. I contacted Kinray (Cardinal
Living with psoriasis was always a daily struggle for me. The constant flare-ups, the unbearable itching, and the visible patches on my skin—psoriasis wasn’t just uncomfortable, it affected my confidence and how I felt about myself. Over the years, I tried countless treatments, from creams to light
This community is dedicated to sharing experiences, insights, and support for those using Deucravacitinib in their journey to manage psoriasis. Whether you’ve been using this supplement for a while, are considering trying it, or just want to learn more, you’re in the right place. # What we’re all ab
Community discussions are sourced from public Reddit threads. Content reflects individual opinions and is not medical advice.
No community discussions found for Risankizumab yet.
Deucravacitinib is a TYK2 Inhibitor, while Risankizumab belongs to the Biologic (IL-23 Inhibitor) class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles. Deucravacitinib is administered via Oral, whereas Risankizumab uses Subcutaneous. Route of administration can affect onset of action and patient adherence.
Risankizumab carries 2 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..
This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.